Humacyte Secures Patent Protection for Bioengineered Esophagus Through 2041
核心洞察
Humacyte received U.S. patent approval for its bioengineered esophagus (搜索) composition, providing intellectual property protection until 2041 for patients with damaged esophageal tissue.
The "Tubular Prostheses (Esophagus (搜索))" patent covers key structural and mechanical attributes including size, strength, and production methods for esophageal replacement applications.
The company has now secured composition of matter coverage for bioengineered trachea (搜索), esophagus (搜索), and urinary conduits (搜索) across the United States, Europe, Canada, and Australia.
Humacyte, Inc. (Nasdaq: HUMA) announced the allowance of a U.S. patent covering the composition of a bioengineered esophagus (搜索) that can be produced using the company's proprietary regenerative tissue engineering platform. The patent, titled "Tubular Prostheses (Esophagus)," provides protection through 2041 for key structural and mechanical attributes designed for esophageal replacement, including size, strength, and methods of production.
The patent represents a significant expansion of Humacyte's intellectual property portfolio for advanced tissue constructs intended to replace damaged airways, upper digestive, and urinary tracts in patients. According to Rob Kirkton, Ph.D., Executive Director of New Product and Process Development at Humacyte, "Bioengineered trachea (搜索), esophagus (搜索), and urinary conduits (搜索) represent novel treatment programs that target high unmet patient needs as well as highlight the versatility of our regenerative tissue engineering platform and the breadth of our product pipeline."
Global Patent Coverage Expansion
With this latest patent grant, Humacyte has secured composition of matter coverage for bioengineered trachea (搜索), esophagus (搜索), and urinary conduits (搜索) across multiple jurisdictions, including the United States, Europe, Canada, and Australia. This international patent protection represents an important expansion of coverage for Humacyte's regenerative tissue engineering platform.
The Tubular Prostheses patent family encompasses both composition and methods claims for advanced tissue constructs, providing comprehensive intellectual property protection for the company's innovative approach to tissue replacement therapy.
Preclinical Development Progress
Advanced tissue constructs for tracheal, esophageal, and urinary conduit replacement have been evaluated in early preclinical models, with plans for future optimization and testing in large animal models. These advanced tissue construct product candidates form one component of Humacyte's broad product pipeline, which also includes acellular tissue engineered vessels (ATEV™), Coronary Tissue Engineered Vessels (CTEV), and the BioVascular Pancreas™ (BVP™).
All of these products can be produced using the same bioengineering technology and manufacturing platform as Humacyte's Symvess (搜索)™ product, demonstrating the versatility and scalability of the company's regenerative tissue engineering approach.
Strategic Development Plans
Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte, expressed satisfaction with the continued expansion of patent protection, stating, "We are pleased to continue to expand the protection surrounding our bioengineered tissue platform and related novel product candidates. We plan to align ourselves with corporate partners where appropriate to accelerate the development of these programs."
The esophageal replacement and other advanced tissue constructs remain investigational products and have not been approved for sale by the FDA or any other regulatory agency.
Company Background and Existing Approvals
Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. The company's initial product candidates, a portfolio of acellular tissue engineered vessels (ATEVs), are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma (搜索) repair, arteriovenous access for hemodialysis, and peripheral artery disease (搜索).
Notably, a Biologics License Application for the ATEV in the vascular trauma (搜索) indication was approved by the FDA in December 2024. Humacyte's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. The ATEV also received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.